
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte's stock outlook is bolstered by a 10% year-over-year growth in Jakafi demand across all indications, supported by stable channel inventory levels. The company's first dermatology product, Opzelura, also demonstrated significant growth, achieving revenues of $188 million, indicating strong patient demand for both atopic dermatitis and vitiligo treatments. Furthermore, Incyte raised its fiscal year 2025 revenue guidance to $4.23 billion - $4.32 billion, driven by improved forecasts for Jakafi and other oncology products, showcasing robust operational execution and a positive sentiment in the broader market.
Bears say
Incyte faces significant downside risks that threaten its financial stability, primarily stemming from eroding pricing power for its leading drug, Jakafi, and poor performance in its earlier-stage pipeline. Clinical and regulatory setbacks related to Jakafi combinations could exacerbate these challenges, leading to potential declines in revenue and diminished market competitiveness. Furthermore, risks such as poor drug uptake, reimbursement obstacles, heightened competition, and safety concerns surrounding marketed products contribute to a negative outlook for Incyte's financial performance.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares